Literature DB >> 1196754

Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis.

W J Jusko, L L Mosovich, L M Gerbracht, M E Mattar, S J Yaffe.   

Abstract

Single oral doses of 6.25 mg/kg of dicloxacillin suspension were given to ten cystic fibrosis (CF) patients and eight normal subjects. Peak serum concentrations and areas under the concentration versus time curves for dicloxacillin were variable and, on average, were 2 1/2 times lower in the CF patients. The time of occurrence of the peak serum concentration was similar in both groups and the total urinary recovery of dicloxacillin was normal or increased in the CF patients, suggesting that the intestinal absorption of the drug was unaffected by the disease. The low serum concentrations in the CF patients were caused by unusually high renal clearances of dicloxacillin which average 282 +/- 135 compared to 95 +/- 28 ml/min/1.73 sq m in the normal subjects. Creatinine clearances were also elevated in the CF patients by 55% on average, while urea clearances were normal. The serum protein binding of dicloxacillin was similar in both groups of subjects. Because the rapid excretion results in low and variable serum concentrations of the antibiotic, treatment of CF patients with dicloxacillin may warrant use of increased or more frequent doses and monitoring of serum antibiotic levels.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1196754

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  37 in total

1.  Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.

Authors:  Timothy H Waterhouse; Stefanie Redmann; Stephen B Duffull; John A Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

2.  Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.

Authors:  M LeBel; M G Bergeron; F Vallée; C Fiset; G Chassé; P Bigonesse; G Rivard
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 3.  Cystic fibrosis. Infection and immunity to Staphylococcus aureus and Haemophilus influenzae.

Authors:  D P Greenberg; H R Stutman
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 4.  Pharmacokinetics of drugs in cystic fibrosis.

Authors:  M Spino
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

5.  Sedation with Propofol for Bronchoscopy in Cystic Fibrosis Lung Transplant Recipients.

Authors:  Carrie Ho; Don Hayes; Medhi Khosravi; Mark L Splaingard; Dmitry Tumin; Eric A Lloyd
Journal:  Lung       Date:  2018-05-24       Impact factor: 2.584

Review 6.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

7.  Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis.

Authors:  A Hedman; G Alván; B Strandvik; A Arvidsson
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

8.  Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis.

Authors:  A Hedman; Y Adan-Abdi; G Alvan; B Strandvik; A Arvidsson
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

Review 9.  Cystic fibrosis--a challenging masquerader.

Authors:  B C Hilman
Journal:  Clin Rev Allergy       Date:  1983-03

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.